Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS opened at $0.03 on Friday. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.70. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The business’s fifty day simple moving average is $0.04 and its 200 day simple moving average is $0.07.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.